U-Ploid Biotechnologies aims to revolutionize IVF for Age-Related Infertility.
Millions of women around the world face the emotional and financial toll of age-related infertility. As more individuals choose to start families later in life, the demand for effective fertility treatments has never been higher. U-Ploid Biotechnologies is a venture-backed startup on a mission to transform the landscape of in vitro fertilization (IVF).
U-Ploid is developing treatments that are designed to improve the quality of older egg cells, and in doing so addressing the growing unmet need for age-related infertility treatments. Instead of solely relying on stimulating the ovaries to produce more eggs, their method enhances the intrinsic quality of existing eggs. The company is also focused on building a highly-scalable solution that allows for effective integration into existing IVF clinic worldwide.
Age-related decline in egg quality is a significant factor contributing to infertility. Traditional IVF treatments often fall short for older women, leading to multiple failed cycles and increased stress. U-Ploid’s technology focuses on repairing the decades of damage that eggs accumulate over time. By enhancing the health of these older eggs, the company aims to increase their viability within an IVF cycle.
U-Ploid is preparing to collaborate with leading fertility clinics globally and is gearing up for clinical studies to validate the efficacy and safety of their platform.
U-Ploid Biotechnologies was founded in 2024 and is based in the UK.
Subscribe for alerts on new companies featured on Startups.Bio
View all recently featured startups